We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.30 | 0.68% | 44.24 | 44.47 | 43.728 | 43.87 | 13,247,504 | 00:58:24 |
Bristol-Myers Squibb Co. (BMY) said a Phase 3 study of its nivolumab treatment for melanoma was stopped early after an analysis by an independent Data Monitoring Committee showed evidence of superior overall survival compared with another therapy.
Nivolumab is designed to target an immune-cell pathway known as PD-1 ("programmed death receptor 1"), which acts as a brake on the immune system to prevent it from attacking healthy cells. Cancer cells can exploit the mechanism by latching on and using PD-1 to escape destruction by the body's immune system. By blocking the interaction, nivolumab allows the immune system to attack cancer cells.
Bristol-Myers, Merck & Co., Roche Holding AG and other companies are racing to bring new immunotherapy drugs to what analysts predict will be a multibillion-dollar market.
Bristol Myers shares rose 2.6% to $49.55 in recent after-hours trading.
--Peter Loftus and Ron Winslow contributed to this article.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions